Repatha – pharmaceutical daily

January 25, 2019 Off

Amgen takes Repatha to china for patients with cardiovascular diseases

Amgen’s Repatha will now be used as the first PCSK9 inhibitor in China for adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of myocardial infarction, stroke and coronary revascularization.

February 21, 2017 Off

Amgen gets more options for using Repatha, EU approves single-dosing

By Dino Mustafić

Amgen on Tuesday got clearance from the European Commission (EC) for a new single-dose delivery option for its Repatha cardiovascular drug.

November 18, 2015 Off

UK cost watchdog turns down Amgen’s new cholesterol drug

By Dino Mustafić

Amgen’s new injectable cholesterol drug Repatha has been turned down for use on Britain’s state health service, underscoring a worldwide debate about the value of such pricey medicines.